Compare Citius Pharmaceuticals Inc (CTXR) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Synchrony Financial — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Synchrony Financial trades at $72.8 (market cap $23.99B). The key difference: Synchrony Financial is far larger — about 1761.4× Citius Pharmaceuticals Inc's market cap, and Synchrony Financial pays a 1.84% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Synchrony Financial for 29 Days on average.
| CTXR | SYF | |
|---|---|---|
Market Cap | $13.62M | $23.99B |
Volume | 132,438 | 3,813,027 |
Sector | Health | Financials |
52-Week High | $1.82 | $88.47 |
52-Week Low | $0.48 | $63.78 |
Typical Hold Time | 17 Days | 29 Days |
Enterprise Value | $3.79M | $24.23B |
Dividend Yield | — | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
Synchrony Financial (SYF) trades at $73.72, up 2.49% with strong technical support at $72 and resistance at $75. The stock shows compelling value with a P/E of 7.56 and ROE of 22.23%, supported by three consecutive earnings beats. Recent partnerships with OpenAI and Vetspire highlight strategic growth initiatives in AI-driven commerce and veterinary financing expansion.
SYF presents an attractive investment case with undervalued fundamentals and positive analyst sentiment, though technical indicators show mixed signals with RSI suggesting potential overbought conditions. Key risks include consumer credit quality concerns and competitive pressures in the financial services sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
